Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75

Organotypic Culture Model of Pancreatic Cancer Demonstrates that Stromal Cells Modulate E-Cadherin, β-Catenin, and Ezrin Expression in Tumor Cells

(2009) Fieke E.M. Froeling et al.   AMERICAN JOURNAL OF PATHOLOGY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer

(2009) Sudeepta Aggarwal et al.   GYNECOLOGIC ONCOLOGY

The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity

(2009) S. C. Alley et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker

(2008) E. Oflazoglu et al.   CLINICAL CANCER RESEARCH

Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70

(2008) J. A. McEarchern et al.   CLINICAL CANCER RESEARCH